Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter StudyCollin M. Blakely, David M. Jablons, Greg M. Allen et al.|Journal of Clinical Oncology|2024Cited by 65
Phase II trial of neoadjuvant osimertinib for surgically resectable <i>EGFR</i>-mutated non-small cell lung cancer.Jacqueline V. Aredo, Collin M. Blakely, Anatoly Urisman et al.|Journal of Clinical Oncology|2023Cited by 23